Nöromüsküler Blokajın Geri Dönüşünde Sugammadeks Uygulanan Radikal Robotik Prostatektomi Hastalarında Pre ve Postoperatif Eosinofil / Lenfosit ve Bazofil / Lenfosit Oranının Karşılaştırılması

Year 2020, Volume: 6 Issue: 1, 42 - 46, 01.01.2020

Ozkan Gorgulu Bora Dınc Zeki Ertug

Abstract

Amaç: Sugammadex, anesteziyoloji pratiğindeki nöromüsküler blokajın iyileşmesinde giderek daha fazla kullanılan yeni bir ajandır. Önemli yararları vardır, ancak risksiz değildir. En önemli yan etki aşırı duyarlılıktır. Eozinofil ve bazofilin lenfosite ELR ve BLR oranının, aşırı duyarlılık durumlarında klinik olarak uygun olduğu önerildiği için, ELR ve / veya BLRʼde, sugammadeksin alerjik karakterini yansıttığı varsayılmıştır. Bu hipotezi değerlendirmek için hastaların preoperatif ve postoperatif ELR ve NLRʼlerini karşılaştırmayı amaçladık. Gereç ve Yöntemler: Elektif robotik radikal prostatektomi yapılan ASA I-II hastaları çalışmaya dahil edildi. Hasta verileri, elektronik hasta veri sistemi SARUS taranarak üretildi. ELR ve BLR, tam kan sayımlarından hesaplandı. Bulgular: Toplam 46 hasta ortalama yaş 64,06±6,4 yıl dahil edildi. ELR postoperatif dönemde anlamlı olarak azaldı p

Keywords

Eozinofil lenfosit oranı, Bazofil Lenfosit oranı, Sugammadeks, Hipersensitivite, Alerji, Anafilaksi

Comparison of Pre and Postoperative Eosinophil/ Lymphocyte and Basophil/Lymphocyte Ratio in Patients of Radical Robotic Prostatectomy who were Administered Sugammadex for the Reversal of Neuromuscular Blockade

Abstract

Objective: Sugammadex is a new agent that is increasingly used in the recovery of neuromuscular blockade in anesthesiology practice. It has significant benefits, but is not risk-free. The most important side effect is hypersensitivity. Since the ratio of eosinophil and basophil to lymphocyte ELR and BLR is suggested to be clinically appropriate in cases of hypersensitivity, it has been assumed that sugammadex reflects allergic character in ELR and / or BLR. In order to evaluate this hypothesis, we aimed to compare the preoperative and postoperative ELR and NLR of the patients. Material and Methods: ASA I-II patients undergoing elective robotic radical prostatectomy were included in the study. Patient data were generated by scanning the electronic patient data system SARUS . ELR and BLR were calculated from whole blood counts. Results: A total of 46 patients mean age 64.06±6.4 years were included. ELR decreased significantly p

Keywords

Eosinophil lymphocyte ratio, Basophil lymphocyte ratio, Sugammadex, Hypersensitivity

References

• 1. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002;41(2):266-70.
• 2. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 2007;106(2):283-8.
• 3. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006;104(4):667-74.
• 4. Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: A comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009;110(5):1020-5.
• 5. Park JY. Benefits and risks of sugammadex. Korean J. Anesthesiol 2015;68(1):1-2.
• 6. Craig RG1, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 2009;64(1):55-65.
• 7. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD. Pathogenesis and classification of eosinophil disorders: A review of recent developments in the field. Expert Rev Hematol 2012;5(2):157-76.
• 8. Tahamiler R, Yener M, Çanakçıoğlu S. Alerjik rinitli hastalarda serum ve nazal eozinofilik katyonik proteinin immünoterapi etkinliğinin değerlendirilmesindeki rolü. Kulak Burun Boğaz Ihtis Derg 2006;16(4):155-9.
• 9. Selçuk A, Fırat Y, Akdoğan Ö, Kaymakçı M, Olcay I. Allerjik rinit tanısında serum eozinofilik katyonik protein kullanımı. KBB-Forum 2006;5(1):25-8.
• 10. Özdemir Ö. Erken ilaç hipersensitivite reaksiyonlarında bazofil aktivasyonu ve bazofil aktivasyon testi (BAT). İstanbul Med J 2017;18:109-13.
• 11. Mangodt EA, Van Gasse AL, Bastiaensen A, Decuyper II, Uyttebroek A, Faber M. Flow-assisted basophil activation tests in immediate drug hypersensitivity: Two decades of Antwerp experience. Acta Clin Belg 2016;71:19-25.
• 12. Yenigun A, Sezen S, Calim OF, Ozturan O. Evaluation of the eosinophil-to-lymphocyte ratio in pediatric patients with allergic rhinitis. Am J Rhinol Allergy 2016;30(2):21-5.
• 13. Brescia G, Pedruzzi B, Barion U, Cinetto F, Giacomelli L, Martini A, Marioni G. Are neutrophil-, eosinophil-, and basophil-to-lymphocyte ratios useful markers for pinpointing patients at higher risk of recurrent sinonasal polyps? Am J Otolaryngol 2016;37(4):339-45.
• 14. Ewan PW, Dugué P, Mirakian R, Dixon TA, Harper JN, Nasser SM. BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp Allergy 2010;40(1):15-31.
• 15. Harper NJ, Dixon T, Dugué P, Edgar DM, Fay A, Gooi HC, Herriot R, Hopkins P, Hunter JM, Mirakian R, Pumphrey RS, Seneviratne SL, Walls AF, Williams P, Wildsmith JA, Wood P, Nasser AS, Powell RK, Mirakhur R, Soar J. Working Party of the Association of Anaesthetists of Great Britain and Ireland. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009;64(2):199-211.
• 16. Gibbs NM, Sadleir PH, Clarke RC, Platt PR. Survival from perioperative anaphylaxis in Western Australia 2000-2009. Br J Anaesth 2013;111(4):589-93.
• 17. Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. Anaesth Intensive Care 2014;42(1):7-9.
• 18. Menéndez-Ozcoidi L, Ortiz-Gómez JR, OlaguibelRibero JM, Salvador-Bravo MJ. Allergy to low dose sugammadex. Anaesthesia 2011;66(3):217-9.
• 19. Min KC, Woo T, Assaid C, McCrea J, Gurner MD, Sisk CM, Adkinson F, Herring WJ. Incidence of hypersensitivity and anaphylaxis with sugammadex. Journal of Clinical Anesthesia 2018;47:67-73.